Related Experiment Video
Updated: Aug 20, 2026

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
Published on: May 18, 2020
Industry perspective for biotech products
1Novartis Pharma AG, Technical Research & Development Quality Assurance, Basel, Switzerland. Annemarie.moeritz@pharma.novartis.com
Abstract:
This presentation, held at the Joint PDA/EMEA Virus Safety Forum, provided an industry perspective on virus safety for biotech products. After discussion of the various groups of biologicals for human use, the presentation focused on a specific group of biologicals, the cell-derived rDNA products. The current authority guidelines of this group of well-defined biotech products were discussed, and a representative case study addressing virus safety aspects was presented. Questions for discussion were raised which illustrated the need for discussion between regulators and industry concerning updated guidance for this group of biologicals.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Upstream Processing
Production of Pharmaceuticals
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinical Trials: Overview
Synthetic Biology
Golden rice
Golden rice is a genetically modified...

